Nexium, Prilosec Stomach Cancer Problems

Austin Kirk

By Austin Kirk
Posted October 5, 2018


Nexium and Prilosec are among the most widely recognized brand-name medications on the market, and are used by millions of Americans. Although most consumers believe the heartburn drugs are safe and carry few serious side effects, our product liability lawyers have been representing individuals nationwide in recent years who suffered serious kidney problems from proton pump inhibitors (PPI).

As more is learned about the potential side effects users may face, the scope of cases being evaluated by Saiontz & Kirk, P.A. has been expanded to also include a review of potential Prilosec and Nexium stomach cancer lawsuits as well. To find out whether you or a loved one may be entitled to financial compensation as a result of the drug makers’ failure to warn about this potential risk, request a free consultation and claim evaluation.

Contact Our Lawyers To Review a STOMACH CANCER CASE

Saiontz & Kirk, PA, Attorneys & Lawyers, Baltimore, MD

Concerns about the link between Nexium and stomach cancer started to gain more widespread attention late last year, following the publication of two studies that indicate users may face a substantially greater risk of developing this serious disease.

In November 2017, a study published in the medical journal BMJ Open concluded that there was a threefold increased incidence of stomach cancer among Nexium, Prilosec and other PPI users.

Researchers examined data from a population based cohort study involving nearly 800,000 users of proton pump inhibitors from Sweden between 2005 and 2012. While the increased risk of Nexium stomach cancer problems seen among both genders and all age groups, the study found that users under the age of 40 faced a more than 22x greater incidence. In contrast, users of Zantac and other histamin-2 receptor antagonists, which are a competing class of heartburn drugs, did not face any increased risk.

These findings were released around the same time as another study published in the medical journal Gut, which indicated that long-term use of Nexium and other PPI drugs may dramatically increased the risk of developing stomach cancer. Researchers reviewed data on more than 63,000 individuals from Hong Kong over a period of 8 years.

Nexium and other PPI drugs are known to be associated with a worsening of gastric atrophy, particularly among individuals with Helicobacter pylori (HP) infections. In this second study, researchers identified individuals with gastric cancer following HP therapy, reviewing data on more than 63,000 individuals from Hong Kong over a period of 8 years.

Again no increased risk of stomach cancer problems was seen with the other heartburn drugs, yet side effects of proton pump inhibitors (PPI) were associated with an overall 2.4 fold increased risk. That risk increased to 5.04 after 1 year of use, 6.65 after 2 years use and 8.34 after 3 years. The adjusted absolute risk difference for PPI vs. non-use of the drugs was 4.29 additional gastric cancer cases per 10,000 “person-years” of use.

Concerns about the failure to properly warn about the Nexium stomach cancer risk were highlighted in a letter published online by the medical journal Gut on December 12, 2017, which indicates that the cancer side effects could have been realized decades ago, before so many individuals were exposed to the risk of stomach cancer.

The authors question why the manufacturers of Nexium and other PPI drugs have not done studies to address the gastric cancer problems associated with long-term use of their drugs. The potential link between stomach cancer and PPI treatment should have been anticipated by the late 1980s, according to the letter.

The stomach cancer risk from Nexium, Prilosec and other PPI “should have been realized decades ago before exposing so many patients to a risk of a serious disease.”


There are currently thousands of Nexium lawsuits, Prilosec lawsuits, Prevacid lawsuits, Protonix lawsuits, Dexilant lawsuits and other claims pending in the federal court system against the manufacturers of PPI drugs pending in courts nationwide, each raising similar allegations that users and the medical community were not adequately warned about the risk of serious kidney problems, such as acute interstitial nephritis, chronic kidney disease and renal failure.

As potential stomach cancer lawsuits are reviewed in the coming weeks and months, it is expected that the size and scope of this litigation will expand and that users will be entitled to financial compensation due to the drug makers’ apparent decision to place their desire for profits before consumer safety.

Early detection and diagnosis of gastric cancer is critical for prompt treatment. If users had been warned about the stomach cancer risk with Nexium, Prilosec and other PPI, many individuals may have avoided this devastating disease by choosing a different heartburn treatment or more closely monitoring for signs and symptoms of gastric cancer, such as:

  • Indigestion
  • Bloated Feeling After Meals
  • Heartburn
  • Nausea
  • Loss of Appetite
  • Stomach Pain
  • Bloody Stool
  • Vomiting
  • Weight Loss
  • Yellowish Skin or Eyes
  • Trouble Swallowing
  • Constipation
  • Diarrhea
  • Fatigue

To review whether you, a friend or family member may be entitled to pursue financial compensation as a result of stomach cancer from Nexium, Prilosec, Prevacid or another PPI, request a free consultation and case evaluation.

All Nexium and Prilosec stomach cancer lawsuits will be investigated on a contingency fee basis, meaning there are never any fees or expenses unless a recovery is obtained.


No Comments • Add Your Comments

Add Your Comments

  • Have Your Comments Reviewed by a Lawyer

    Provide contact information below and additional private comments if you want an attorney to contact you to review a potential case.

    The information below will not be published to this page.

  • NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

  • This field is for validation purposes and should be left unchanged.